- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02946619
Health Benefits of Expressive Writing Among Chinese Breast Cancer Survivors
Reducing Psychological Burdens Among Chinese Breast Cancer Survivors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 91776
- Herald Cancer Association
-
-
Texas
-
Houston, Texas, United States, 77204
- University of Houston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1) having a breast cancer diagnosis; 2) completing breast cancer surgery within five years; and 3) being comfortable writing and speaking Chinese (i.e. Mandarin or Cantonese)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control Condition
Participants in the control group were asked to write for three weeks about facts regarding their cancer and its treatment for three sessions.
|
|
|
Experimental: Self-regulation condition
For the self-regulation condition, each weekly writing assignment covers a different task.
During session one, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; in session two, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
|
|
|
Experimental: Enhanced self-regulation condition
For the enhanced self-regulation condition, each weekly writing assignment covers a different task.
During session one, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; during session two, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in quality of life score as assessed by the Functional Assessment of Cancer Therapy Scale (FACT)
Time Frame: Baseline, 1 month, 3 months, and 6 months follow-ups after the intervention.
|
The Functional Assessment of Cancer Therapy Scale (FACT) is a 27-item measure of health-related quality of life (Cella & Tulsky,1993), which assesses perceived life quality in four different facets, including physical well-being (7 items,score range 0 - 28), social well-being (7 items, score range 0 - 28), emotional well-being (6 items, score range 0-24), and functional well-being (7 items, score range 0-28). A higher subscale score indicates better functioning in the corresponding domain. Total score is computed by summing up the scores of the four subscales. Total score ranges from 0 to 108. A higher score indicates better quality of life. |
Baseline, 1 month, 3 months, and 6 months follow-ups after the intervention.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in posttraumatic stress disorder (PTSD), as assessed by the PTSD Symptom Scale - Self Report version (PSS-SR)
Time Frame: Baseline, 1 month, 3 months, and 6 months follow-ups after the intervention.
|
The scale contains 17 items reflecting the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition -Text Revision (DSM-IV-TR) symptoms of post-traumatic stress disorder (Foa, Riggs, Dancu, & Rothbaum, 1993). Score can be reported in terms of total score or the score of the three subscales (Re-experiencing, Avoidance and Hyperarousal). The score ranges for the three sub-scales are: Re-experiencing symptoms (5 items, 0-15), Avoidance symptoms (7 items, 0 -21) and Hyperarousal symptoms (5 items, 0-15). Each subscale score is computed by summing up the scores of the corresponding items. For each subscale, a higher score indicates more severe symptoms. The total score is computed by summing up the scores of the three subscales. The total score ranges from 0 to 51. A higher score indicated more severe PTSD symptoms. |
Baseline, 1 month, 3 months, and 6 months follow-ups after the intervention.
|
|
Change in fatigue as assessed by Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F)
Time Frame: Baseline, 1 month, 3 months, and 6 months follow-ups after the intervention.
|
The scale contains 13 items.
Total score is computed by summing up the scores of all the 13 items.
The total score ranges from 0 to 52.
A higher score indicates more severe fatigue symptoms.
|
Baseline, 1 month, 3 months, and 6 months follow-ups after the intervention.
|
|
Change in depressive symptoms as assessed by Center for Epidemiologic Studies Depression Scale (CES-D).
Time Frame: Baseline, 1 month, 3 months, and 6 months follow-ups after the intervention.
|
The scale contains 10 items.
Total score is computed by summing up the scores of all the 10 items.
Total score ranges from 0 to 30.
A higher scores indicates more severe depression symptoms.
|
Baseline, 1 month, 3 months, and 6 months follow-ups after the intervention.
|
|
Change in anxiety as assessed by Brief Symptom Inventory (BSI)-anxiety dimension
Time Frame: Baseline, 1 month, 3 months, and 6 months follow-ups after the intervention.
|
The scale contains 6 items.
Total score is computed by summing up the scores of all the 6 items.
Total score ranges from 0 - 24.
A higher score indicates more severe anxiety symptoms.
|
Baseline, 1 month, 3 months, and 6 months follow-ups after the intervention.
|
|
Change in physical symptoms as assessed by the Physical Symptoms Checklist
Time Frame: Baseline, 1 month, 3 months, and 6 months follow-ups after the intervention.
|
The scale contains 10 items.
Total score is computed by summing up the scores of all the 10 items.
Total score ranges from 0 - 300.
A higher score indicates more severe physical symptoms.
|
Baseline, 1 month, 3 months, and 6 months follow-ups after the intervention.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Qian Lu, Ph.D., MD, University of Houston
Publications and helpful links
General Publications
- Chu Q, Wu IHC, Tang M, Tsoh J, Lu Q. Temporal relationship of posttraumatic stress disorder symptom clusters during and after an expressive writing intervention for Chinese American breast cancer survivors. J Psychosom Res. 2020 Aug;135:110142. doi: 10.1016/j.jpsychores.2020.110142. Epub 2020 May 16.
- Chu Q, Wu IHC, Lu Q. Expressive writing intervention for posttraumatic stress disorder among Chinese American breast cancer survivors: the moderating role of social constraints. Qual Life Res. 2020 Apr;29(4):891-899. doi: 10.1007/s11136-019-02385-5. Epub 2020 Jan 3.
- Lu Q, Gallagher MW, Loh A, Young L. Expressive Writing Intervention Improves Quality of Life Among Chinese-American Breast Cancer Survivors: A Randomized Controlled Trial. Ann Behav Med. 2018 Oct 22;52(11):952-962. doi: 10.1093/abm/kax067.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MRSGT-10-011-01-CPPB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
Clinical Trials on Self-Regulation Condition
-
University of HoustonAmerican Cancer Society, Inc.; Herald Cancer AssociationCompletedBreast Cancer | Breast NeoplasmUnited States
-
University of VictoriaSocial Sciences and Humanities Research Council of CanadaCompleted
-
UNC Lineberger Comprehensive Cancer CenterCompletedBreast Neoplasms | Body Weight ChangesUnited States
-
Columbia UniversityNational Institute on Aging (NIA)Completed
-
New York Blood CenterCompleted
-
Jacobs University Bremen gGmbHGuangdong Provincial People's Hospital; Maastricht University; Hong Kong Baptist... and other collaboratorsCompletedCARDIOVASCULAR DISEASES | HEART DISEASESChina, Germany, Netherlands
-
University of MichiganEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMedication Adherence | Self-regulationUnited States
-
Oklahoma State UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Enrolling by invitationChild WellbeingUnited States
-
Sir Mortimer B. Davis - Jewish General HospitalCompleted